Innovent Biologics Inks Potential 105 Billion Drug Deal with Pfizer XENE Q1 2026 Earnings EPS Beat in PreRevenue Biotech Stock Edges Higher CFTC Escalates Legal Battle Sues Rhode Island Over Prediction Market Regulation